PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.87%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
3.04%
Gross profit growth at 50-75% of TSM's 5.56%. Martin Whitman would question if cost structure or brand is lagging.
55.04%
Positive EBIT growth while TSM is negative. John Neff might see a substantial edge in operational management.
55.04%
Positive operating income growth while TSM is negative. John Neff might view this as a competitive edge in operations.
280.21%
Positive net income growth while TSM is negative. John Neff might see a big relative performance advantage.
333.33%
Positive EPS growth while TSM is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
333.33%
Positive diluted EPS growth while TSM is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
-6.68%
Reduced diluted shares while TSM is at 0.69%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
88.98%
OCF growth above 1.5x TSM's 23.19%. David Dodd would confirm a clear edge in underlying cash generation.
58.42%
FCF growth under 50% of TSM's 298.53%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
241.96%
10Y revenue/share CAGR at 50-75% of TSM's 350.23%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
241.96%
5Y revenue/share CAGR 1.25-1.5x TSM's 187.42%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
116.71%
3Y revenue/share CAGR above 1.5x TSM's 66.95%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-116.65%
Negative 10Y OCF/share CAGR while TSM stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-116.65%
Negative 5Y OCF/share CAGR while TSM is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-106.12%
Negative 3Y OCF/share CAGR while TSM stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
53.94%
Below 50% of TSM's 275.42%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
53.94%
Below 50% of TSM's 191.52%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-22.07%
Negative 3Y CAGR while TSM is 457.18%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
684.61%
10Y equity/share CAGR above 1.5x TSM's 334.86%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
684.61%
5Y equity/share CAGR above 1.5x TSM's 164.00%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
159.52%
3Y equity/share CAGR above 1.5x TSM's 40.86%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.58%
Our AR growth while TSM is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-10.19%
Inventory is declining while TSM stands at 23.70%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-4.07%
Negative asset growth while TSM invests at 8.35%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
4.11%
75-90% of TSM's 4.95%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
-42.16%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-1.45%
Our R&D shrinks while TSM invests at 19.10%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
0.43%
SG&A declining or stable vs. TSM's 133.58%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.